vs
艺达思集团（IEX）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是艺达思集团的1.6倍（$622.0M vs $398.4M），Royalty Pharma plc净利率更高（34.4% vs 30.1%，领先4.3%），艺达思集团同比增速更快（16.7% vs 4.8%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs -29.4%）
艺达思集团是一家公开上市的工业制造企业，专注于流体系统与特种工程产品的研发和生产，产品广泛应用于工业制造、生命科学、食品安全等多个领域，可为全球各行业客户提供高性能定制化解决方案。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
IEX vs RPRX — 直观对比
营收规模更大
RPRX
是对方的1.6倍
$398.4M
营收增速更快
IEX
高出11.9%
4.8%
净利率更高
RPRX
高出4.3%
30.1%
两年增速更快
RPRX
近两年复合增速
-29.4%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $398.4M | $622.0M |
| 净利润 | $120.0M | $214.2M |
| 毛利率 | 99.9% | — |
| 营业利润率 | 43.3% | 62.4% |
| 净利率 | 30.1% | 34.4% |
| 营收同比 | 16.7% | 4.8% |
| 净利润同比 | 25.7% | 2.9% |
| 每股收益（稀释后） | $1.61 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IEXRPRX
| Q2 26 | $398.4M | — | ||
| Q1 26 | $407.7M | — | ||
| Q4 25 | $899.1M | $622.0M | ||
| Q3 25 | $878.7M | $609.3M | ||
| Q2 25 | $865.4M | $578.7M | ||
| Q1 25 | $814.3M | $568.2M | ||
| Q4 24 | $862.9M | $593.6M | ||
| Q3 24 | $798.2M | $564.7M |
净利润IEXRPRX
| Q2 26 | $120.0M | — | ||
| Q1 26 | $128.3M | — | ||
| Q4 25 | $128.3M | $214.2M | ||
| Q3 25 | $127.8M | $288.2M | ||
| Q2 25 | $131.6M | $30.2M | ||
| Q1 25 | $95.5M | $238.3M | ||
| Q4 24 | $123.2M | $208.2M | ||
| Q3 24 | $119.1M | $544.0M |
毛利率IEXRPRX
| Q2 26 | 99.9% | — | ||
| Q1 26 | 94.9% | — | ||
| Q4 25 | 43.1% | — | ||
| Q3 25 | 44.5% | — | ||
| Q2 25 | 45.3% | — | ||
| Q1 25 | 45.3% | — | ||
| Q4 24 | 42.5% | — | ||
| Q3 24 | 44.3% | — |
营业利润率IEXRPRX
| Q2 26 | 43.3% | — | ||
| Q1 26 | 45.0% | — | ||
| Q4 25 | 20.4% | 62.4% | ||
| Q3 25 | 21.1% | 70.1% | ||
| Q2 25 | 21.7% | 36.3% | ||
| Q1 25 | 17.4% | 94.0% | ||
| Q4 24 | 19.2% | 60.9% | ||
| Q3 24 | 21.0% | — |
净利率IEXRPRX
| Q2 26 | 30.1% | — | ||
| Q1 26 | 31.5% | — | ||
| Q4 25 | 14.3% | 34.4% | ||
| Q3 25 | 14.5% | 47.3% | ||
| Q2 25 | 15.2% | 5.2% | ||
| Q1 25 | 11.7% | 41.9% | ||
| Q4 24 | 14.3% | 35.1% | ||
| Q3 24 | 14.9% | 96.3% |
每股收益（稀释后）IEXRPRX
| Q2 26 | $1.61 | — | ||
| Q1 26 | $1.71 | — | ||
| Q4 25 | $1.71 | $0.49 | ||
| Q3 25 | $1.70 | $0.67 | ||
| Q2 25 | $1.74 | $0.07 | ||
| Q1 25 | $1.26 | $0.55 | ||
| Q4 24 | $1.61 | $0.46 | ||
| Q3 24 | $1.57 | $1.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $586.2M | $618.7M |
| 总债务越低越好 | — | $9.0B |
| 股东权益账面价值 | $4.0B | $9.7B |
| 总资产 | $6.9B | $19.6B |
| 负债/权益比越低杠杆越低 | — | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资IEXRPRX
| Q2 26 | $586.2M | — | ||
| Q1 26 | $580.0M | — | ||
| Q4 25 | $580.0M | $618.7M | ||
| Q3 25 | $593.8M | $938.9M | ||
| Q2 25 | $568.2M | $631.9M | ||
| Q1 25 | $594.1M | $1.1B | ||
| Q4 24 | $620.8M | $929.0M | ||
| Q3 24 | $633.2M | $950.1M |
总债务IEXRPRX
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $1.8B | $9.0B | ||
| Q3 25 | $1.9B | $8.9B | ||
| Q2 25 | $1.9B | $8.0B | ||
| Q1 25 | $2.0B | $7.6B | ||
| Q4 24 | $2.0B | $7.6B | ||
| Q3 24 | $2.1B | $7.6B |
股东权益IEXRPRX
| Q2 26 | $4.0B | — | ||
| Q1 26 | $4.0B | — | ||
| Q4 25 | $4.0B | $9.7B | ||
| Q3 25 | $4.0B | $9.6B | ||
| Q2 25 | $4.0B | $9.5B | ||
| Q1 25 | $3.9B | $9.8B | ||
| Q4 24 | $3.8B | $10.3B | ||
| Q3 24 | $3.8B | $10.3B |
总资产IEXRPRX
| Q2 26 | $6.9B | — | ||
| Q1 26 | $6.9B | — | ||
| Q4 25 | $6.9B | $19.6B | ||
| Q3 25 | $7.0B | $19.3B | ||
| Q2 25 | $6.9B | $18.3B | ||
| Q1 25 | $6.8B | $17.6B | ||
| Q4 24 | $6.7B | $18.2B | ||
| Q3 24 | $7.0B | $18.0B |
负债/权益比IEXRPRX
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 0.45× | 0.92× | ||
| Q3 25 | 0.48× | 0.93× | ||
| Q2 25 | 0.46× | 0.84× | ||
| Q1 25 | 0.50× | 0.78× | ||
| Q4 24 | 0.52× | 0.74× | ||
| Q3 24 | 0.55× | 0.74× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $86.0M | — |
| 自由现金流率自由现金流/营收 | 21.6% | — |
| 资本支出强度资本支出/营收 | 4.4% | — |
| 现金转化率经营现金流/净利润 | — | 3.86× |
| 过去12个月自由现金流最近4个季度 | $654.3M | — |
8季度趋势，按日历期对齐
经营现金流IEXRPRX
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $209.5M | $827.1M | ||
| Q3 25 | $203.5M | $702.6M | ||
| Q2 25 | $161.7M | $364.0M | ||
| Q1 25 | $105.7M | $596.1M | ||
| Q4 24 | $172.6M | $742.5M | ||
| Q3 24 | $205.3M | $703.6M |
自由现金流IEXRPRX
| Q2 26 | $86.0M | — | ||
| Q1 26 | $189.8M | — | ||
| Q4 25 | $189.8M | — | ||
| Q3 25 | $188.7M | — | ||
| Q2 25 | $146.9M | — | ||
| Q1 25 | $91.4M | — | ||
| Q4 24 | $157.1M | — | ||
| Q3 24 | $191.6M | — |
自由现金流率IEXRPRX
| Q2 26 | 21.6% | — | ||
| Q1 26 | 46.6% | — | ||
| Q4 25 | 21.1% | — | ||
| Q3 25 | 21.5% | — | ||
| Q2 25 | 17.0% | — | ||
| Q1 25 | 11.2% | — | ||
| Q4 24 | 18.2% | — | ||
| Q3 24 | 24.0% | — |
资本支出强度IEXRPRX
| Q2 26 | 4.4% | — | ||
| Q1 26 | 15.6% | — | ||
| Q4 25 | 2.2% | — | ||
| Q3 25 | 1.7% | — | ||
| Q2 25 | 1.7% | — | ||
| Q1 25 | 1.8% | — | ||
| Q4 24 | 1.8% | — | ||
| Q3 24 | 1.7% | — |
现金转化率IEXRPRX
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 1.63× | 3.86× | ||
| Q3 25 | 1.59× | 2.44× | ||
| Q2 25 | 1.23× | 12.06× | ||
| Q1 25 | 1.11× | 2.50× | ||
| Q4 24 | 1.40× | 3.57× | ||
| Q3 24 | 1.72× | 1.29× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IEX
暂无分部数据
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
